Literature DB >> 21068758

Prostate cancer: HIFU is effective, but associated morbidity still remains unclear.

John F Ward.   

Abstract

Entities:  

Mesh：

Year:  2010        PMID： 21068758     DOI： 10.1038/nrurol.2010.176

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  10 in total

1.  Radical prostatectomy versus watchful waiting in early prostate cancer.

Authors:  Anna Bill-Axelson; Lars Holmberg; Mirja Ruutu; Michael Häggman; Swen-Olof Andersson; Stefan Bratell; Anders Spångberg; Christer Busch; Stig Nordling; Hans Garmo; Juni Palmgren; Hans-Olov Adami; Bo Johan Norlén; Jan-Erik Johansson
Journal:  N Engl J Med       Date:  2005-05-12       Impact factor: 91.245

2.  The perfect storm of overutilization.

Authors:  Ezekiel J Emanuel; Victor R Fuchs
Journal:  JAMA       Date:  2008-06-18       Impact factor: 56.272

3.  Mortality results from the Göteborg randomised population-based prostate-cancer screening trial.

Authors:  Jonas Hugosson; Sigrid Carlsson; Gunnar Aus; Svante Bergdahl; Ali Khatami; Pär Lodding; Carl-Gustaf Pihl; Johan Stranne; Erik Holmberg; Hans Lilja
Journal:  Lancet Oncol       Date:  2010-07-02       Impact factor: 41.316

4.  Multicentric oncologic outcomes of high-intensity focused ultrasound for localized prostate cancer in 803 patients.

Authors:  Sebastien Crouzet; Xavier Rebillard; Daniel Chevallier; Pascal Rischmann; Gilles Pasticier; Gregory Garcia; Olivier Rouviere; Jean-Yves Chapelon; Albert Gelet
Journal:  Eur Urol       Date:  2010-07-03       Impact factor: 20.096

5.  Morbidity associated with repeated transrectal high-intensity focused ultrasound treatment of localized prostate cancer.

Authors:  Andreas Blana; Sebastian Rogenhofer; Roman Ganzer; Peter J Wild; Wolf F Wieland; Bernhard Walter
Journal:  World J Urol       Date:  2006-07-19       Impact factor: 4.226

6.  A retrospective analysis illustrating the substantial clinical and economic burden of prostate cancer.

Authors:  E D Crawford; L Black; M Eaddy; E J Kruep
Journal:  Prostate Cancer Prostatic Dis       Date:  2010-02-02       Impact factor: 5.554

7.  Screening and prostate-cancer mortality in a randomized European study.

Authors:  Fritz H Schröder; Jonas Hugosson; Monique J Roobol; Teuvo L J Tammela; Stefano Ciatto; Vera Nelen; Maciej Kwiatkowski; Marcos Lujan; Hans Lilja; Marco Zappa; Louis J Denis; Franz Recker; Antonio Berenguer; Liisa Määttänen; Chris H Bangma; Gunnar Aus; Arnauld Villers; Xavier Rebillard; Theodorus van der Kwast; Bert G Blijenberg; Sue M Moss; Harry J de Koning; Anssi Auvinen
Journal:  N Engl J Med       Date:  2009-03-18       Impact factor: 91.245

8.  Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context.

Authors:  Gerrit Draisma; Ruth Etzioni; Alex Tsodikov; Angela Mariotto; Elisabeth Wever; Roman Gulati; Eric Feuer; Harry de Koning
Journal:  J Natl Cancer Inst       Date:  2009-03-10       Impact factor: 13.506

9.  Post-treatment prostate biopsies in the era of three-dimensional conformal radiotherapy: what can they teach us?

Authors:  Almudena Zapatero; Ricardo Mínguez; Santiago Nieto; Carmen Martín de Vidales; Feliciano García-Vicente
Journal:  Eur Urol       Date:  2008-05-07       Impact factor: 20.096

10.  Biochemical failure as a determinant of distant metastasis and death in prostate cancer treated with radiotherapy.

Authors:  Alan Pollack; Alexandra L Hanlon; Benjamin Movsas; Gerald E Hanks; Robert Uzzo; Eric M Horwitz
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-09-01       Impact factor: 7.038
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.